No association of anti-osteoporosis drugs with COVID-19-related outcomes in women: a nationwide cohort study.

COVID-19 Cohort Studies Female Humans Osteoporosis / drug therapy Pharmaceutical Preparations Retrospective Studies SARS-CoV-2
Bisphosphonates COVID-19 Denosumab Mortality Osteoporosis Teriparatide

Journal

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
ISSN: 1433-2965
Titre abrégé: Osteoporos Int
Pays: England
ID NLM: 9100105

Informations de publication

Date de publication:
Jan 2022
Historique:
received: 12 04 2021
accepted: 10 07 2021
pubmed: 18 8 2021
medline: 18 1 2022
entrez: 17 8 2021
Statut: ppublish

Résumé

This study was performed to evaluate whether the use of drugs in the treatment of osteoporosis in women is associated with COVID-19 outcomes. The results showed that the risk of hospitalization, intensive care unit admission, and mortality was not altered in individuals taking anti-osteoporosis drugs, suggesting no safety issues during a COVID-19 infection. Whether patients with COVID-19 receiving anti-osteoporosis drugs have lower risk of worse outcomes has not been reported yet. The aim of this study was to evaluate the association of anti-osteoporosis drug use with COVID-19 outcomes in women. Data obtained from a nationwide, multicenter, retrospective cohort of patients diagnosed with COVID-19 from March 11th to May 30th, 2020 was retrieved from the Turkish Ministry of Health Database. Women 50 years or older with confirmed COVID-19 who were receiving anti-osteoporosis drugs were compared with a 1:1 propensity score-matched COVID-19 positive women who were not receiving these drugs. The primary outcomes were hospitalization, ICU (intensive care unit) admission, and mortality. A total of 1997 women on anti-osteoporosis drugs and 1997 control patients were analyzed. In the treatment group, 1787 (89.5%) women were receiving bisphosphonates, 197 (9.9%) denosumab, and 17 (0.9%) teriparatide for the last 12 months. Hospitalization and mortality rates were similar between the treatment and control groups. ICU admission rate was lower in the treatment group (23.0% vs 27.0%, p = 0.013). However, multivariate analysis showed that anti-osteoporosis drug use was not an independent associate of any outcome. Hospitalization, ICU admission, and mortality rates were similar among bisphosphonate, denosumab, or teriparatide users. Results of this nationwide study showed that preexisting use of anti-osteoporosis drugs in women did not alter the COVID-19-related risk of hospitalization, ICU admission, and mortality. These results do not suggest discontinuation of these drugs during a COVID-19 infection.

Identifiants

DOI: 10.1007/s00198-021-06067-2 PMID: 34402949 PMC: PMC8369875
pubmed: 34402949
doi: 10.1007/s00198-021-06067-2
pii: 10.1007/s00198-021-06067-2
pmc: PMC8369875
doi:

Substances chimiques

Pharmaceutical Preparations 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

273-282

Informations de copyright

© 2021. International Osteoporosis Foundation and National Osteoporosis Foundation.

Références

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497–506. https://doi.org/10.1016/S0140-6736(20)30183-5
doi: 10.1016/S0140-6736(20)30183-5 pubmed: 31986264 pmcid: 7159299
Deng SQ, Peng HJ (2020) Characteristics of and public health responses to the coronavirus disease 2019 outbreak in China. J Clin Med 9:575. https://doi.org/10.3390/jcm9020575
doi: 10.3390/jcm9020575 pmcid: 7074453
World Health Organization. Coronavirus disease 2019 (COVID-19) [Internet]. https://www.who.int/ Accessed 13 June 2021
WHO Coronavirus Disease (COVID-19) Dashboard. Available at ‘ https://covid19.who.int/ ’. Accessed 13 June 2021
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS, China Medical Treatment Expert Group for Covid-19 (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382:1708–1720. https://doi.org/10.1056/NEJMoa2002032
doi: 10.1056/NEJMoa2002032 pubmed: 32109013
Cao Z, Li T, Liang L, Wang H, Wei F, Meng S, Cai M, Zhang Y, Xu H, Zhang J, Jin R (2020) Clinical characteristics of coronavirus disease 2019 patients in Beijing. China PLoS One 15:e0234764. https://doi.org/10.1371/journal.pone.0234764
Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP (2020) The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol 20:363–374. https://doi.org/10.1038/s41577-020-0311-8
doi: 10.1038/s41577-020-0311-8 pubmed: 32346093
Merad M, Martin JC (2020) Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol 20:355–362. https://doi.org/10.1038/s41577-020-0331-4
doi: 10.1038/s41577-020-0331-4 pubmed: 32376901 pmcid: 7201395
Zeng F, Huang Y, Guo Y, Yin M, Chen X, Xiao L, Deng G (2020) Association of inflammatory markers with the severity of COVID-19: a meta-analysis. Int J Infect Dis 96:467–474. https://doi.org/10.1016/j.ijid.2020.05.055
doi: 10.1016/j.ijid.2020.05.055 pubmed: 32425643 pmcid: 7233226
Michelena X, Borrell H, López-Corbeto M, López- Lasanta M, Moreno E, Pascual-Pastor M, Erra A, Serrat M, Espartal E, Antón S, Añez GA, Caparrós-Ruiz R, Pluma A, Trallero-Araguaz E, Barcelo-Bru M, Almirall M, De Agustin JJ, Llados J, Julia A, Marsal S (2020) Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum 50:564–570. https://doi.org/10.1016/j.semarthrit.2020.05.001
doi: 10.1016/j.semarthrit.2020.05.001 pubmed: 32425260 pmcid: 7229730
Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, Izadi Z, Jacobsohn L, Katz P, Lawson-Tovey S, Mateus EF, Rush S, Schmajuk G, Simard J, Strangfeld A, Trupin L, Wysham KD, Bhana S, Costello W, Grainger R, Hausmann JS, Liew JW, Sirotich E, Sufka P, Wallace ZS, Yazdany J, Machado PM, Robinson PC, COVID-19 Global Rheumatology Alliance (2020) Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry. Ann Rheum Dis 79:859–866. https://doi.org/10.1136/annrheumdis-2020-217871
Consensus development conference diagnosis, prophylaxis, and treatment of osteoporosis (1993) Am J Med 94:646–650. https://doi.org/10.1016/0002-9343(93)90218-e
Kanis JA, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF) (2019) Executive summary of the European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Calcif Tissue Int 104:235–238. https://doi.org/10.1007/s00223-018-00512-x
doi: 10.1007/s00223-018-00512-x pubmed: 30796490 pmcid: 6422308
Gittoes NJ, Criseno S, Appelman-Dijkstra NM, Bollerslev J, Canalis E, Rejnmark L, Hassan-Smith Z (2020) Endocrinology in the time of COVID-19: management of calcium metabolic disorders and osteoporosis. Eur J Endocrinol 183:G57–G65. https://doi.org/10.1530/EJE-20-0385
doi: 10.1530/EJE-20-0385 pubmed: 32396134 pmcid: 7938011
Yu EW, Tsourdi E, Clarke BL, Bauer DC, Drake MT (2020) Osteoporosis management in the era of COVID-19. J Bone Miner Res 35:1009–1013. https://doi.org/10.1002/jbmr.4049
doi: 10.1002/jbmr.4049 pubmed: 32406536
Landewé RB, Machado PM, Kroon F, Bijlsma HW, Burmester GR, Carmona L, Combe B, Galli M, Gossec L, Iagnocco A, Isaacs JD, Mariette X, McInnes I, Mueller-Ladner U, Openshaw P, Smolen JS, Stamm TA, Wiek D, Schulze-Koops H (2020) EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann Rheum Dis 79:851–858. https://doi.org/10.1136/annrheumdis-2020-217877
doi: 10.1136/annrheumdis-2020-217877 pubmed: 32503854
Girgis CM, Clifton-Brigh RJ (2020) Osteoporosis in the age of COVID-19. Osteoporos Int 31:1189–1191. https://doi.org/10.1007/s00198-020-05413-0
doi: 10.1007/s00198-020-05413-0 pubmed: 32346775 pmcid: 7187664
Ji W, Huh K, Kang M, Hong J, Bae GH, Lee R, Na Y, Choi H, Gong SY, Choi YH, Ko KP, Im JS, Jung J (2020) Effect of underlying comorbidities on the infection and severity of COVID-19 in Korea: a nationwide case-control study. J Korean Med Sci 35:e237. https://doi.org/10.3346/jkms.2020.35.e237
doi: 10.3346/jkms.2020.35.e237 pubmed: 32597048 pmcid: 7324262
Blanch-Rubió J, Soldevila-Domenech N, Tío L, Llorente-Onaindia J, Ciria-Recasens M, Polino L, Gurt A, de la Torre R, Maldonado R, Monfort J, Group TCS (2020) Influence of anti-osteoporosis treatments on the incidence of COVID-19 in patients with non-inflammatory rheumatic conditions. Aging (Albany NY) 12:19923–19937. https://doi.org/10.18632/aging.104117
doi: 10.18632/aging.104117
https://www.who.int/tools/atc-ddd-toolkit/methodology . Accessed 13 June 2021
Ayranci U, Orsal O, Orsal O, Arslan G, Emeksiz DF (2010) Menopause status and attitudes in Turkish midlife female population: an epidemiological study. BMC Womens Health 10:1. https://doi.org/10.1186/1472-6874-10-1
doi: 10.1186/1472-6874-10-1 pubmed: 20064263 pmcid: 2822813
Tuzun S, Eskiyurt N, Akarirmak U, Saridogan M, Senocak M, Johansson H, Kanis JA, Turkish Osteoporosis Society (2012) Incidence of hip fracture and prevalence of osteoporosis in Turkey: the FRACTURK study. Osteoporos Int 23:949–955. https://doi.org/10.1007/s00198-011-1655-5
doi: 10.1007/s00198-011-1655-5 pubmed: 21594756
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612. https://doi.org/10.7326/0003-4819-150-9-200905050-00006
Baron R, Ferrari S, Russell GG (2011) Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 48:677–692. https://doi.org/10.1016/j.bone.2010.11.020
doi: 10.1016/j.bone.2010.11.020 pubmed: 21145999
Russell RG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733–759. https://doi.org/10.1007/s00198-007-0540-8
doi: 10.1007/s00198-007-0540-8 pubmed: 18214569
Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S, Recurrent Fracture Trial HORIZON (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809. https://doi.org/10.1056/NEJMoa074941
doi: 10.1056/NEJMoa074941 pubmed: 17878149
Colón-Emeric CS, Mesenbrink P, Lyles KW, Pieper CF, Boonen S, Delmas P, Eriksen EF, Magaziner J (2010) Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res 25:91–97. https://doi.org/10.1359/jbmr.090704
doi: 10.1359/jbmr.090704 pubmed: 19580467
Brufsky A, Marti JLG, Nasrazadani A, Lotze MT (2020) Boning up: amino-bisphophonates as immunostimulants and endosomal disruptors of dendritic cell in SARS-CoV-2 infection. J Transl Med 18:261. https://doi.org/10.1186/s12967-020-02433-6
doi: 10.1186/s12967-020-02433-6 pubmed: 32600410 pmcid: 7322393
Chiu YG, Ritchlin CT (2017) Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis. Expert Opin Biol Ther 17:119–128. https://doi.org/10.1080/14712598.2017.1263614
doi: 10.1080/14712598.2017.1263614 pubmed: 27871200
Cheng ML, Fong L (2014) Effects of RANKL-targeted therapy in immunity and cancer. Front Oncol 3:329. https://doi.org/10.3389/fonc.2013.00329
doi: 10.3389/fonc.2013.00329 pubmed: 24432249 pmcid: 3882875
Kobayashi-Sakamoto M, Tamai R, Kiyoura Y (2015) Beyond bone remodeling–emerging functions of osteoprotegerin in host defense and microbial infection. Integr Mol Med 2:384–390. https://doi.org/10.15761/IMM.1000173
doi: 10.15761/IMM.1000173
McMahan K, Yu J, Mercado NB, Loos C, Tostanoski LH, Chandrashekar A, Liu J, Peter L, Atyeo C, Zhu A, Bondzie EA, Dagotto G, Gebre MS, Jacob-Dolan C, Li Z, Nampanya F, Patel S, Pessaint L, Van Ry A, Blade K, Yalley-Ogunro J, Cabus M, Brown R, Cook A, Teow E, Andersen H, Lewis MG, Lauffenburger DA, Alter G, Barouch DH (2021) Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 590:630–634. https://doi.org/10.1038/s41586-020-03041-6
doi: 10.1038/s41586-020-03041-6 pubmed: 33276369
Sobacchi C, Menale C, Villa A (2019) The RANKL-RANK axis: a bone to thymus round trip. Front Immunol 10:629. https://doi.org/10.3389/fimmu.2019.00629
Diker-Cohen T, Rosenberg D, Avni T, Shepshelovich D, Tsvetov G, Gafter-Gvili A (2020) Risk for infections during treatment with denosumab for osteoporosis: a systematic review and meta-analysis. J Clin Endocrinol Metab 105:dgz322. https://doi.org/10.1210/clinem/dgz322
doi: 10.1210/clinem/dgz322 pubmed: 31899506
Formenti AM, Pedone E, di Filippo L, Ulivieri FM, Giustina A (2020) Are women with osteoporosis treated with denosumab at risk of severe COVID-19? Endocrine 70:203–205. https://doi.org/10.1007/s12020-020-02500-
doi: 10.1007/s12020-020-02500- pubmed: 32951069
Geara AS, Castellanos MR, Bassil C, Schuller-Levis G, Park E, Smith M, Goldman M, Elsayegh S (2010) Effects of parathyroid hormone on immune function. Clin Dev Immunol 2010:418695. https://doi.org/10.1155/2010/418695
doi: 10.1155/2010/418695 pubmed: 20886005 pmcid: 2945648
Castellanos M, Jung E, Park SY, Schuller-Levis G, Odaimi M, Elsayegh S, Kleiner M, Elsoueidi R, Shtaynberg N, Park E (2010) Effect of parathyroid hormone and teriparatide on immune function of human adherent and non-adherent leukocytes. Clin Nephrol 74:83–90. https://doi.org/10.5414/cnp74083
doi: 10.5414/cnp74083 pubmed: 20630127
https://hsgm.saglik.gov.tr/depo/birimler/goc_sagligi/covid19/rehber/COVID-19_Rehberi20200414_eng_v4_002_14.05.2020.pdf . Accessed 13 June 2021

Auteurs

A Atmaca (A)

Department of Endocrinology and Metabolism, School of Medicine, Samsun Ondokuz Mayis University, Samsun, Turkey. atmaca_aysegul@yahoo.com.
ORCID: 0000-0001-6326-6365

I Demirci (I)

Department of Endocrinology and Metabolism, Gulhane Training and Research Hospital, University of Health Sciences Turkey, Ankara, Turkey.

C Haymana (C)

Department of Endocrinology and Metabolism, Gulhane Training and Research Hospital, University of Health Sciences Turkey, Ankara, Turkey.

I Tasci (I)

Department of Internal Medicine Gulhane School of Medicine and Gulhane Training and Research Hospital, University of Health Sciences Turkey, Ankara, Turkey.

I Sahin (I)

Department of Endocrinology and Metabolism, School of Medicine, Malatya Inonu University, Malatya, Turkey.

E Cakal (E)

Department of Endocrinology and Metabolism, School of Medicine, Diskapi Yildirim Beyazit Training and Research Hospital, University of Health Sciences Turkey, Ankara, Turkey.

N Ata (N)

Department of Strategy Development, Ministry of Health, Republic of Turkey, Ankara, Turkey.

S Dagdelen (S)

Department of Endocrinology and Metabolism, School of Medicine, Hacettepe University, Ankara, Turkey.

S Salman (S)

Department of Endocrinology and Metabolism, Medica Clinic, Istanbul, Turkey.

R Emral (R)

Department of Endocrinology and Metabolism, School of Medicine, Ankara University, Ankara, Turkey.

M Sahin (M)

Department of Endocrinology and Metabolism, School of Medicine, Ankara University, Ankara, Turkey.

O Celik (O)

Public Hospitals General Directorate, Ministry of Health, Republic of Turkey, Ankara, Turkey.

T Demir (T)

Department of Endocrinology and Metabolism, School of Medicine, Dokuz Eylul University, Izmir, Turkey.

D Ertugrul (D)

Department of Endocrinology and Metabolism, Kecioren Training and Research Hospital, School of Medicine, University of Health Sciences Turkey, Ankara, Turkey.

U Unluturk (U)

Department of Endocrinology and Metabolism, School of Medicine, Hacettepe University, Ankara, Turkey.

M Caglayan (M)

Ankara Provincial Health Directorate, Ankara, Turkey.

I Satman (I)

Department of Endocrinology and Metabolism, School of Medicine, Istanbul University, Istanbul, Turkey.
Turkish Institute of Public Health and Chronic Diseases, Istanbul, Turkey.

A Sonmez (A)

Department of Endocrinology and Metabolism, Gulhane School of Medicine and Gulhane Training and Research Hospital, University of Health Sciences Turkey, Ankara, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › No association of anti-osteoporosis drugs with...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › No association of anti-osteoporosis drugs with...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › No association of anti-osteoporosis drugs with...
questionsmedicales.fr › Maladies métaboliques et nutritionnelles › Maladies métaboliques › Maladies osseuses métaboliques › Ostéoporose › No association of anti-osteoporosis drugs with...
questionsmedicales.fr › Préparations pharmaceutiques › No association of anti-osteoporosis drugs with...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › No association of anti-osteoporosis drugs with...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Virus du SRAS › SARS-CoV-2 › No association of anti-osteoporosis drugs with...